Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.81 USD | +1.69% | +0.01% | +3.30% |
29/05 | Transcript : Hologic, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 10:00 AM | |
22/05 | FDA classifies recall of Hologic's implant as 'most serious' | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company benefits from high valuations in earnings multiples.
- The company's enterprise value to sales, at 4.32 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.30% | 1.72TCr | B+ | ||
+7.01% | 22TCr | B | ||
+11.01% | 19TCr | B- | ||
+19.20% | 14TCr | B- | ||
+30.79% | 11TCr | A- | ||
+1.48% | 6.46TCr | A- | ||
+13.95% | 5.24TCr | B+ | ||
-0.16% | 4.85TCr | B+ | ||
-6.20% | 3.8TCr | A | ||
+0.91% | 3.56TCr | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HOLX Stock
- Ratings Hologic, Inc.